Swedish Orphan Biovitrum
315.8
SEK
+0.51 %
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+0.51%
-4.53%
-0.5%
+4.57%
+1.48%
+21.46%
+70.51%
+63.35%
+561.8%
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Read moreMarket cap
112.42B SEK
Turnover
88.24M SEK
Revenue
26.03B
EBIT %
21.61 %
P/E
27.77
Dividend yield-%
-
Financial calendar
29.4
2025
Interim report Q1'25
8.5
2025
General meeting '25
15.7
2025
Interim report Q2'25
ShowingAll content types
Swedish Orphan Biovitrum AB: Sobi's latest haemophilia research to be presented at EAHAD 2025
Swedish Orphan Biovitrum AB: Sobi's full year 2024 revenue higher than previous estimate
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools